Melanotan 1 (MT1) Dosage Guide: How Much Should You Take? (2026)

Melanotan 1 (MT1) Dosage Guide: How Much Should You Take? (2026)

Key Takeaways:

• Melanotan 1 (MT1) is available for research purposes only and is not FDA-approved for human therapeutic use^[1]
• Research protocols typically use subcutaneous doses ranging from 0.25 mg to 2.0 mg per injection^[2]
• The peptide has a half-life of approximately 30-40 minutes, requiring multiple daily administrations in research settings
• Clinical trials have used loading doses of 0.16 mg/kg followed by maintenance doses of 0.08 mg/kg^[1]
• Bioavailability via subcutaneous injection is approximately 85-90% compared to intravenous administration^[2]
• All research applications require proper medical supervision and institutional oversight
• Storage requires refrigeration at 36-46°F (2-8°C) to maintain peptide stability

How Melanotan 1 (MT1) Works in the Body

Melanotan 1 (MT1) is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) with the amino acid sequence [Nle⁴-D-Phe⁷]-α-MSH.^[1] The peptide contains 13 amino acids with a molecular weight of 1,646.9 Da and demonstrates high binding affinity for melanocortin-1 receptors (MC1R) with a Kd value of approximately 0.23 nM.^[2] Understanding these pharmacokinetic properties is essential for determining appropriate dosing protocols in research applications.

The mechanism of action involves binding to melanocortin receptors, particularly MC1R, which activates adenylyl cyclase and increases intracellular cyclic adenosine monophosphate (cAMP) levels by 15-20 fold within 30 minutes of administration. This activation triggers downstream signaling cascades that stimulate melanogenesis through increased tyrosinase activity and eumelanin synthesis.^[1] The peptide's half-life of 30-40 minutes in human plasma necessitates frequent dosing to maintain therapeutic concentrations.^[2]

"MT-1 demonstrated dose-dependent increases in skin pigmentation with peak effects observed 72-96 hours post-administration at doses of 0.16 mg/kg."^[1]

Bioavailability studies indicate that subcutaneous administration achieves 85-90% of intravenous bioavailability, making it the preferred route for research protocols. The peptide undergoes rapid clearance through renal filtration and enzymatic degradation, with approximately 60% eliminated unchanged in urine within 6 hours of administration.^[2] These pharmacokinetic characteristics directly influence dosing frequency and total daily dose requirements in research settings.

Standard Melanotan 1 (MT1) Dosage Ranges (By Form)

Research protocols utilize various administration routes for Melanotan 1 (MT1), with subcutaneous injection being the most common method due to optimal bioavailability and ease of administration.^[1] Clinical studies have established specific dosing parameters for each route based on pharmacokinetic analysis and receptor saturation curves.^[2]

Evidence note: The dose ranges above reflect circulating community and research-protocol practice, aggregated from multiple independent sources. They are not derived from controlled human trials, and specific pharmacokinetic figures (bioavailability, half-life, peak timing) are estimates that have not been validated in published human studies.

Subcutaneous administration protocols in phase 1 clinical trials used initial doses of 0.25 mg with escalation to maximum doses of 2.0 mg based on individual response and tolerance.^[1] The bioavailability advantage of subcutaneous injection (85-90%) compared to other routes makes it the gold standard for research applications requiring consistent plasma concentrations.

Intramuscular injection provides sustained release characteristics with peak plasma concentrations occurring 45-60 minutes post-injection compared to 15-30 minutes for subcutaneous administration.^[2] However, the lower bioavailability (70-80%) necessitates dose adjustments of approximately 15-20% to achieve equivalent systemic exposure.

Intranasal delivery offers rapid onset of action with detectable plasma levels within 5-10 minutes, but the significantly lower bioavailability (25-35%) and short duration of action limit its utility in research protocols requiring sustained exposure.^[1] Topical formulations demonstrate minimal systemic absorption (5-15%) and are primarily used for localized research applications.^[2]

Melanotan 1 (MT1) Dosage by Use Case

Melanogenesis Research Protocols

Research investigating melanin synthesis pathways typically employs subcutaneous doses of 0.16 mg/kg as loading doses followed by maintenance doses of 0.08 mg/kg administered twice daily.^[1] Clinical trials examining photoprotective effects used this dosing regimen for 10-14 day study periods with UV exposure protocols.^[2] Peak melanogenic activity occurs 48-72 hours after initial administration, requiring consistent dosing to maintain elevated cAMP levels in melanocytes.

Research protocols often incorporate a 3-day loading phase with 0.16 mg/kg daily followed by maintenance dosing at 0.08 mg/kg twice daily for the remainder of the study period.^[1] This approach achieves steady-state plasma concentrations within 24-36 hours and maintains receptor saturation throughout the observation period.^[2]

Receptor Pharmacology Studies

MC1R binding studies utilize dose ranges from 0.1-1.0 mg subcutaneously to establish dose-response relationships and receptor occupancy curves. Research examining receptor selectivity typically employs escalating doses starting at 0.25 mg with incremental increases of 0.25 mg every 48 hours until maximum response is achieved.^[1]

Competitive binding assays often use single doses of 0.5-1.0 mg to achieve near-maximal receptor occupancy (>90%) for pharmacological characterization studies.^[2] The short half-life necessitates multiple sampling points within the first 2-4 hours post-administration to capture peak binding activity.

Cell Signaling Research

cAMP signaling pathway studies typically utilize doses of 0.5-1.5 mg subcutaneously to achieve maximal adenylyl cyclase activation.^[1] Research protocols examining downstream signaling cascades often employ divided doses (0.75 mg twice daily) to maintain consistent intracellular cAMP elevation throughout the study period.^[2]

Time-course studies of protein kinase A activation use single bolus doses of 1.0-2.0 mg with serial tissue sampling at 15, 30, 60, and 120 minutes post-administration. These protocols allow for comprehensive characterization of signal transduction kinetics and duration of response.^[1]

Comparative Pharmacology Research

Studies comparing Melanotan 1 to Melanotan 2 typically use equimolar doses adjusted for molecular weight differences, with MT1 doses approximately 15% higher due to its larger molecular size.^[2] Cross-over study designs often employ 1.0 mg MT1 versus 0.85 mg MT2 to achieve equivalent receptor binding potential.

Dose-ranging studies examining potency differences between melanocortin analogs use logarithmic dose escalation protocols starting at 0.1 mg and increasing by half-log increments to maximum doses of 3.0 mg.^[1] These protocols allow for accurate determination of ED50 values and therapeutic index calculations.^[2]

Titration Protocol: How to Ramp Up Safely

Research protocols for Melanotan 1 (MT1) incorporate systematic dose escalation to minimize adverse effects while achieving target receptor occupancy levels.^[1] Clinical trials have established standardized titration schedules based on pharmacokinetic modeling and safety data from phase 1 studies.^[2]

The initial dose of 0.25 mg twice daily represents approximately 25% of the target therapeutic dose and allows for assessment of individual tolerance and receptor sensitivity. This conservative starting approach reduces the incidence of dose-limiting side effects observed in early clinical trials.^[1]

Week 2 escalation to 0.5 mg twice daily (1.0 mg total daily dose) typically produces detectable increases in plasma cAMP levels and early melanogenic responses.^[2] Research protocols monitor vital signs, injection site reactions, and subjective tolerance measures during this escalation phase. If adverse effects occur, protocols typically maintain the current dose for an additional 3-7 days before further escalation.^[1]

The target maintenance dose of 1.0 mg twice daily (2.0 mg total daily) achieves near-maximal receptor occupancy (85-90%) while maintaining an acceptable safety profile in research settings.^[2] Some protocols incorporate a de-escalation strategy, reducing to 0.75 mg twice daily if side effects develop during maintenance dosing.

Dose reduction protocols typically decrease by 50% increments with monitoring periods of 48-72 hours between adjustments.^[1] Complete discontinuation follows a tapering schedule over 3-5 days to avoid potential rebound effects, though these are rarely observed with Melanotan 1 due to its short half-life.^[2]

How Long Should You Take Melanotan 1 (MT1)?

Research study durations for Melanotan 1 (MT1) vary significantly based on the specific research objectives and endpoints being measured.^[1] Phase 1 clinical trials typically employed treatment periods of 10-21 days to assess acute safety and pharmacokinetic parameters.^[2] Longer-term studies examining sustained effects have extended treatment periods up to 8-12 weeks with careful safety monitoring.

Short-term research protocols (7-14 days) focus on acute pharmacological responses and immediate biochemical changes following MT1 administration.^[1] These studies demonstrate peak melanogenic activity within 48-72 hours of initial dosing, with maximal pigmentation changes observed by day 7-10 of continuous treatment.^[2] Plasma concentrations reach steady-state within 24-36 hours due to the peptide's short half-life of 30-40 minutes.

Medium-term protocols (2-6 weeks) allow for assessment of sustained physiological responses and adaptation mechanisms.^[1] Research indicates that melanogenic responses plateau after 14-21 days of continuous dosing, suggesting receptor desensitization or downstream pathway saturation.^[2] cAMP signaling responses remain elevated throughout 4-week treatment periods, indicating maintained receptor binding capacity.

Extended research protocols (6-12 weeks) have been used to evaluate long-term safety parameters and potential tolerance development.^[1] These studies demonstrate gradual reduction in response magnitude after 6-8 weeks of continuous treatment, with approximately 20-30% decrease in peak cAMP responses compared to initial treatment weeks.^[2] Recovery of full responsiveness occurs within 2-3 weeks following treatment discontinuation.

Treatment cessation does not require gradual tapering due to MT1's short half-life and absence of physical dependence mechanisms.^[1] Research protocols typically implement immediate discontinuation with monitoring periods of 7-14 days to assess washout kinetics and return to baseline parameters.^[2] Plasma concentrations become undetectable within 4-6 hours of final administration, with complete clearance of metabolites within 24-48 hours.

Administration Protocol: How to Inject Melanotan 1 (MT1)

Subcutaneous injection represents the standard administration method for Melanotan 1 (MT1) research protocols due to optimal bioavailability (85-90%) and consistent absorption characteristics.^[1] Proper injection technique is critical for maintaining research integrity and ensuring accurate dosing in clinical studies.^[2] Research facilities must follow standardized administration protocols to minimize variability and maximize data quality.

Required Equipment and Preparation

Research protocols utilize insulin syringes with 29-31 gauge needles and 0.5-1.0 mL capacity for precise volume delivery.^[1] The short needle length (1/2 inch or 12.7 mm) is optimal for subcutaneous injection depth of 4-6 mm into the adipose tissue layer.^[2] Reconstituted MT1 solutions require gentle mixing to avoid peptide degradation, with final concentrations typically prepared at 1-2 mg/mL for accurate dosing.

Storage requirements mandate refrigeration at 36-46°F (2-8°C) with protection from light to maintain peptide stability.^[1] Reconstituted solutions remain stable for 7-14 days when stored properly, though research protocols often prepare fresh solutions every 3-5 days to ensure maximum potency.^[2] For detailed reconstitution procedures, refer to our how to reconstitute Melanotan 1 (MT1) guide.

Injection Site Selection and Rotation

Clinical research protocols utilize three primary injection sites: abdominal area (2 inches from umbilicus), anterior thigh (middle third of quadriceps), and posterior upper arm (deltoid region). Site rotation follows a systematic pattern to prevent lipodystrophy and ensure consistent absorption rates across treatment periods.^[1] Each injection site should be separated by at least 1 inch from previous injections within the same anatomical region.^[2]

Abdominal injection sites provide the most consistent absorption profiles with coefficient of variation <15% between injection sites. Thigh injections demonstrate slightly slower absorption (peak plasma levels 45-60 minutes vs 30-45 minutes for abdominal sites) but maintain equivalent bioavailability.^[1] Upper arm sites show higher variability (CV 20-25%) and are typically reserved for protocols requiring multiple daily injections.^[2]

Step-by-Step Administration Protocol

1. Preparation Phase: Verify peptide concentration and calculate injection volume based on prescribed dose (typically 0.25-1.0 mL for standard doses).

2. Hand Hygiene: Perform thorough handwashing for minimum 20 seconds using antimicrobial soap to prevent contamination.^[1]

3. Site Preparation: Clean injection site with 70% isopropyl alcohol using circular motion from center outward, allow 30-60 seconds drying time.^[2]

4. Syringe Preparation: Draw prescribed volume into syringe, eliminate air bubbles by gentle tapping and express excess air through needle.

5. Injection Technique: Pinch skin fold between thumb and forefinger, insert needle at 45-90 degree angle depending on subcutaneous tissue thickness.^[1]

6. Solution Delivery: Inject slowly over 5-10 seconds to minimize tissue trauma and ensure complete delivery.^[2]

7. Needle Withdrawal: Remove needle quickly while maintaining pressure on injection site with sterile gauze for 10-15 seconds.

8. Post-Injection Care: Apply small adhesive bandage if needed, document injection site and time in research records.^[1]

Timing and Frequency Considerations

Research protocols typically schedule injections 8-12 hours apart for twice-daily dosing regimens to maintain consistent plasma concentrations.^[2] Morning injections are often administered 30-60 minutes before UV exposure in photoprotection studies to optimize melanogenic responses. Food intake does not significantly affect subcutaneous absorption, allowing flexible timing relative to meals.^[1]

Injection site reactions occur in approximately 15-20% of research subjects and typically resolve within 24-48 hours without intervention.^[2] Rotating injection sites and using proper technique reduces the incidence of persistent reactions or tissue changes. Research protocols monitor injection sites daily during treatment periods and document any adverse reactions for safety analysis.^[1]

Stacking Melanotan 1 (MT1) for Enhanced Results

Research protocols investigating combination therapies with Melanotan 1 (MT1) focus on synergistic mechanisms and enhanced pharmacological responses.^[1] Combination studies examine both peptide-peptide interactions and peptide-drug combinations to understand potential therapeutic applications and safety profiles.^[2] These research approaches require careful dose adjustment and monitoring protocols to account for pharmacokinetic interactions.

MT1 + UV Radiation Protocols

Clinical research combining MT1 with controlled UV exposure represents the most extensively studied combination approach.^[1] Research protocols typically administer 0.16 mg/kg MT1 subcutaneously 30-60 minutes prior to UV-B exposure at doses of 1-2 minimal erythema dose (MED) units.^[2] This timing optimizes melanocortin receptor activation during peak UV-induced DNA damage periods.

Combination protocols demonstrate 40-60% reduction in UV-induced erythema compared to UV exposure alone, with enhanced melanogenesis responses observed within 48-72 hours.^[1] The synergistic photoprotective effects require precise timing, with MT1 administration >2 hours before UV exposure showing diminished protective efficacy.^[2] Research facilities must maintain strict UV dosimetry protocols to ensure reproducible results across study subjects.

MT1 + Melanocortin Analogs

Comparative research examining MT1 in combination with Melanotan 2 investigates receptor selectivity and potency differences between α-MSH analogs.^[1] Research protocols use reduced doses of each peptide (0.5 mg MT1 + 0.4 mg MT2) to achieve equivalent total melanocortin receptor occupancy while minimizing individual peptide side effects.^[2] These studies demonstrate additive effects on cAMP signaling with approximately 25-30% enhanced response compared to individual peptide administration.

Sequential administration protocols examine temporal effects, with MT1 administered first (longer half-life considerations) followed by MT2 after 2-4 hours to maintain consistent receptor activation.^[1] Cross-tolerance studies indicate minimal desensitization between the two analogs over 14-day treatment periods.^[2]

MT1 + Growth Hormone Releasing Peptides

Research investigating metabolic interactions combines MT1 with growth hormone releasing peptides to examine potential effects on body composition and metabolic parameters. Protocols typically use standard MT1 doses (1.0 mg twice daily) combined with GHRP-6 at 100-200 mcg three times daily with careful monitoring of glucose metabolism and body weight changes.^[1]

These combination studies require extended observation periods (4-8 weeks) due to the different time courses of metabolic versus melanogenic responses.^[2] Preliminary research suggests potential synergistic effects on lean body mass preservation, though larger controlled studies are needed to establish clinical significance.

MT1 + Antioxidant Compounds

Research protocols examining photoprotective mechanisms combine MT1 with various antioxidant compounds including vitamin C, vitamin E, and polyphenolic compounds.^[1] These studies investigate whether enhanced antioxidant capacity can augment MT1's protective effects against UV-induced oxidative stress.^[2] Combination protocols maintain standard MT1 dosing (0.16 mg/kg) while adding oral antioxidant supplementation at therapeutic doses.

Preliminary findings suggest 15-20% enhancement of photoprotective effects when MT1 is combined with high-dose vitamin C (1000 mg daily) and vitamin E (400 IU daily).^[1] These combinations require careful monitoring for potential interactions affecting MT1 absorption or metabolism.^[2]

Factors That Affect Your Melanotan 1 (MT1) Dosage

Individual dosing requirements for Melanotan 1 (MT1) in research settings vary significantly based on multiple physiological and demographic factors.^[1] Understanding these variables is essential for developing appropriate research protocols and interpreting study results across diverse populations.^[2] Dose adjustments based on individual characteristics can improve both safety profiles and research outcomes.

Body Weight and Composition

Research protocols typically calculate MT1 doses based on body weight using 0.08-0.16 mg/kg dosing formulas derived from pharmacokinetic modeling.^[1] Subjects weighing 70 kg receive approximately 5.6-11.2 mg total doses, while 90 kg subjects require 7.2-14.4 mg for equivalent plasma concentrations.^[2] Body composition analysis reveals that lean body mass correlates more strongly with MT1 clearance than total body weight, with correlation coefficients of 0.78 vs 0.62 respectively.

Adipose tissue distribution affects subcutaneous absorption rates, with abdominal adiposity >25% body fat showing 10-15% reduced bioavailability compared to leaner subjects.^[1] Research protocols may increase doses by 0.1-0.2 mg for subjects with BMI >30 kg/m² to achieve equivalent systemic exposure.^[2] Conversely, subjects with BMI <20 kg/m² may require dose reductions of 15-20% to prevent excessive plasma concentrations.

Age-Related Considerations

Age-related changes in peptide metabolism significantly impact MT1 dosing requirements across different age groups.^[1] Subjects over 65 years demonstrate 25-30% slower clearance rates, necessitating dose reductions or extended dosing intervals in research protocols.^[2] Younger subjects (18-30 years) show enhanced clearance with 20-25% higher dose requirements to achieve equivalent plasma concentrations.

Renal function decline with aging (approximately 1 mL/min/1.73m² per year after age 30) directly affects MT1 elimination kinetics.^[1] Research protocols incorporate estimated glomerular filtration rate (eGFR) calculations, with dose reductions of 25% for eGFR 30-60 mL/min/1.73m² and 50% reductions for eGFR <30 mL/min/1.73m².^[2] Elderly subjects also demonstrate increased sensitivity to melanocortin receptor activation, requiring careful dose titration protocols.

Gender Differences

Pharmacokinetic studies reveal significant gender-related differences in MT1 metabolism and distribution.^[1] Female subjects demonstrate 15-20% higher bioavailability following subcutaneous injection, attributed to differences in subcutaneous tissue composition and blood flow patterns.^[2] Research protocols may reduce initial doses by 0.1-0.2 mg for female subjects to account for enhanced absorption characteristics.

Hormonal fluctuations during menstrual cycles affect melanocortin receptor sensitivity, with peak responses observed during follicular phase (days 1-14) compared to luteal phase.^[1] Some research protocols schedule MT1 administration during specific menstrual cycle phases to minimize inter-subject variability in female populations.^[2] Pregnancy and lactation represent absolute contraindications for MT1 research participation due to unknown fetal and neonatal effects.

Hepatic Function Impact

Liver function significantly influences MT1 metabolism through peptidase activity and first-pass effects.^[1] Subjects with mild hepatic impairment (Child-Pugh Class A) require dose reductions of 20-25%, while moderate impairment (Class B) necessitates 40-50% dose reductions.^[2] Severe hepatic impairment (Class C) represents an exclusion criterion for most MT1 research protocols due to unpredictable pharmacokinetics.

Hepatic enzyme induction from concurrent medications can accelerate MT1 metabolism, requiring dose increases of 25-35% to maintain therapeutic plasma levels.^[1] Conversely, enzyme inhibitors may necessitate dose reductions of 15-25% to prevent excessive accumulation.^[2] Research protocols monitor liver function tests at baseline and during treatment periods to detect changes affecting MT1 metabolism.

Concurrent Medication Effects

Drug interactions with MT1 primarily involve medications affecting melanocortin pathways or peptide metabolism.^[1] Concurrent use of β-adrenergic agonists may enhance MT1 effects through synergistic cAMP elevation, requiring dose reductions of 10-20% in research protocols.^[2] Conversely, β-blockers may attenuate MT1 responses, necessitating dose increases of 15-25% to achieve target endpoints.

Medications affecting renal function (ACE inhibitors, NSAIDs, diuretics) can alter MT1 clearance rates by 10-30%, requiring careful monitoring and potential dose adjustments.^[1] Corticosteroids may interfere with melanocortin receptor signaling, reducing MT1 efficacy and requiring protocol modifications or subject exclusion.^[2] Research protocols maintain comprehensive medication histories and monitor for potential interactions throughout study periods.